Outlook Raises $5M From Director-Linked Fund, Reprices 15 Million Warrants

Outlook Therapeutics is a Nasdaq-listed biopharmaceutical company whose entire commercial and regulatory bet rests on a single product: LYTENAVA (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for wet age-related macular degeneration. The drug holds EU and UK marketing authorization and launched commercially in Germany and the UK in June 2025, but European revenues have been negligible and, owing to returns reserves on short-dated initial inventory, reported net revenue for the six months ended March 31, 2026 was negative $1.08 million.

The company's balance sheet reflects the strain. Cash stood at $7.7 million as of March 31, 2026 — before $4.5 million in net proceeds from an April registered direct offering. Current liabilities of $38.9 million outstrip total assets of $21.9 million, producing a stockholders' deficit of $29 million. On a non-GAAP basis, which strips out non-cash warrant fair-value swings, the operating loss for the quarter ended March 31, 2026 was $14.1 million. On February 18, 2026, Nasdaq notified the company that its stock had closed below $1.00 per share for 30 consecutive business days, starting a 180-day compliance clock that expires August 17, 2026.